Currently, prospective data related to the clinical outcomes of PALB2 mutation carriers is lacking and very little information (beyond mutation penetrance) is available to guide clinical management for carriers (affected and unaffected by breast cancer). This evidence concerns the gene PALB2 and breast carcinoma.